文献速递免疫规划传染病防控与疫情报告

美国65岁及以上成人引入13价肺炎球菌结合疫苗后的肺炎链球菌定植研究(2015-2016)

Streptococcus pneumoniae colonization after introduction of 13-valent pneumococcal conjugate vaccine for US adults 65 years of age and older, 2015-2016.
PubMed 文献 · Vaccine · 2019-01-23

该研究在美国四个州对2989名非机构居住的65岁及以上成人进行横断面调查,采集鼻咽和口咽拭子,采用培养和实时PCR检测肺炎链球菌定植及血清型。结果显示定植率极低(1.8%),疫苗型血清型定植仅0.3%,接种与未接种者疫苗型定植率相似(0.2% vs 0.1%),呼吸道症状与定植风险升高相关(调整OR=2.1,95%CI=1.1-3.8)。

要点

  • 65岁及以上成人肺炎链球菌定植率很低,疫苗型血清型定植不足0.5%。
  • 接种与未接种PCV13者疫苗型定植率相似(0.2% vs 0.1%)。
  • 呼吸道症状与肺炎球菌定植风险升高相关(调整OR=2.1)。

核心结论

  • 非机构居住的65岁及以上成人肺炎链球菌定植率极低,疫苗型血清型定植率低于0.5%。
  • 接种与未接种PCV13者疫苗型定植率相似,难以区分PCV13对成人定植的直接效应与间接效应。

研究设计与样本

  • 2015-2016年在美国四个州开展的横断面调查,纳入2989名非机构居住的65岁及以上成人。
  • 采集人口学信息、疾病风险因素、PCV13接种史及鼻咽和口咽拭子,拭子分别处理,采用Quellung反应进行血清分型,并检测抗菌药物敏感性。
  • 鼻咽拭子同时进行实时PCR检测肺炎链球菌及血清分型。

主要发现

  • 2989名参与者中45.3%(1354/2989)接种过PCV13。
  • 45株肺炎链球菌分离株中22株对至少一种受试抗生素不敏感。
  • 接种与未接种者疫苗型定植率分别为0.2%和0.1%。
  • 呼吸道症状与肺炎球菌定植风险升高相关(调整OR:2.1;95%CI=1.1-3.8)。

临床怎么用

  • 在65岁及以上成人中,肺炎链球菌定植率及疫苗型定植率均很低,呼吸道症状者定植风险较高。
  • 儿童PCV13接种可能通过间接效应降低成人疫苗型定植,但本研究难以区分直接与间接效应。

局限性

  • 横断面设计无法确定因果关系。
  • 研究在PCV13成人接种引入后不久开展,且当时PCV13成人覆盖率已较高,难以区分直接与间接效应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Vaccination of children with 13-valent pneumococcal conjugate vaccine (PCV13) led to declines in vaccine-type pneumococcal nasopharyngeal carriage among adults through indirect effects. In August 2014, PCV13 immunization of all U.S. adults ≥65 years of age was recommended. This study sought to define prevalence and serotype distribution of pneumococcal carriage among adults ≥65 years of age and to describe risk factors for colonization soon after introduction of PCV13 in adults. METHODS: A cross-sectional survey of non-institutionalized U.S. adults ≥65 years of age was conducted in four states in 2015-2016. Demographic information, risk factors for disease, PCV13 vaccination history, and nasopharyngeal (NP) and oropharyngeal (OP) swabs were collected. NP and OP swabs were processed separately and pneumococcal isolates were serotyped by Quellung reaction. Antimicrobial susceptibility of pneumococcal isolates was performed. NP swabs also underwent real-time PCR for pneumococcal detection and serotyping. RESULTS: Of 2989 participants, 45.3% (1354/2989) had been vaccinated with PCV13. Fifty-five (1.8%) carried pneumococcus (45 identified by culture and 10 by real-time PCR only) and PCV13 serotypes were found in eight (0.3%) participants. Almost half (22/45) of pneumococcal isolates were not susceptible to at least one of the antibiotics tested. Vaccine-type carriage among vaccinated and unvaccinated individuals was similar (0.2% vs. 0.1%, respectively). Respiratory symptoms were associated with higher odds of pneumococcal colonization (adjusted OR: 2.1; 95% CI = 1.1-3.8). CONCLUSIONS: Pneumococcal carriage among non-institutionalized adults ≥65 years of age was very low. Less than 0.5% of both vaccinated and unvaccinated individuals in our study carried vaccine-type serotypes. Over a decade of PCV vaccination of children likely led to indirect effects in adults. However, given the low vaccine-type carriage rates we observed in an already high PCV13 adult coverage setting, it is difficult to attribute our findings to the direct versus indirect effects of PCV13 on adult carriage.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Milucky J, Carvalho MG, Rouphael N, et al. Streptococcus pneumoniae colonization after introduction of 13-valent pneumococcal conjugate vaccine for US adults 65 years of age and older, 2015-2016. Vaccine. 2019. PMID: 30685247. doi:10.1016/j.vaccine.2018.12.075

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。